Abstract

New Frontiers in Targeted Therapy: ADCETRIS® (Brentuximab vedotin) a CD30 directed Antibody Drug Conjugate

Ashish Gautam, Global Brand Medical Head - ADCETRIS, Takeda Oncology

ADCETRIS® (brentuximab vedotin) is an ADC comprising an anti-CD30 monoclonal antibody attached by a protease-cleavable linker to a microtubule disrupting agent, monomethyl auristatin E (MMAE). The ADC employs a linker system that is designed to be stable in the bloodstream but to release MMAE upon internalization into CD30-positive tumor cells. ADCETRIS is being evaluated broadly in more than 70 ongoing clinical trials, including three Phase 3 studies, the ongoing ECHELON-1 trial in frontline classical Hodgkin lymphoma and the ongoing ECHELON-2 trial in frontline mature T-cell lymphomas, as well as the completed ALCANZA trial in cutaneous T-cell lymphoma. ADCETRIS is indicated for the treatment of adult patients with relapsed or refractory CD30+ Hodgkin lymphoma (HL):1. following autologous stem cell transplant (ASCT) or 2. following at least two prior therapies when ASCT or multi-agent chemotherapy is not a treatment option. ADCETRIS is indicated for the treatment of adult patients with CD30+ HL at increased risk of relapse or progression following ASCT. ADCETRIS is indicated for the treatment of adult patients with relapsed or refractory systemic anaplastic large cell lymphoma (sALCL). The most common adverse events with ADCETRIS of any grade include: peripheral neuropathy, nausea, diarrhea, fatigue, vomiting, alopecia, pruritis, pyrexia, decreased appetite and neutropenia. ADCETRIS has received marketing authorization by regulatory authorities in 66 countries for relapsed or refractory Hodgkin lymphoma and sALCL The presentation will cover the following topics: • Development of brentuximab vedotin • Mechanism pathway of brentuximab vedotin • Data published from brentuximab vedotin studies • Ongoing brentuximab vedotin clinical development